GLP1R and obesity due to melanocortin 4 receptor deficiency: Most anti-obesity medications, including glucagon-like peptide-1 (GLP-1) receptor agonists and extended-release phentermine–topiramate (Qsymia), are currently approved by the United States Food and Drug Administration (FDA) for those 12 years and older [13,14,15].